Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin | Zendy

Saverio Giuseppe Parisi | Zendy; Arianna Loregian | Zendy; Samantha Andreis | Zendy; Giulio Nannetti | Zendy; Silvia Cavinato | Zendy; Monica Basso | Zendy; Renzo Scaggiante | Zendy; Federico Dal Bello | Zendy; Lorenzo Messa | Zendy; Anna Maria Cattelan | Zendy; Giorgio Palù | Zendy

Open Access

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin

Author(s) -

Saverio Giuseppe Parisi,

Arianna Loregian,

Samantha Andreis,

Giulio Nannetti,

Silvia Cavinato,

Monica Basso,

Renzo Scaggiante,

Federico Dal Bello,

Lorenzo Messa,

Anna Maria Cattelan,

Giorgio Palù

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.06.020

Subject(s) - daclatasvir , sofosbuvir , ribavirin , virology , cirrhosis , medicine , hepatitis c virus , human immunodeficiency virus (hiv) , gastroenterology , virus

Effective treatment with direct-acting antiviral drugs against hepatitis C virus (HCV) is a medical need in cirrhotic HIV-HCV co-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research